Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Neuromyelitis Optica Spectrum Disorder Market Poised for Robust Expansion Through 2036 | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Mar 16, 2026, 10:01 ET

      Share this article

      Share this article


      The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026–2036), mainly attributed to the increasing prevalence of NMOSD, growing awareness, advancement in diagnostic techniques, and the launch of emerging therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others, reports DelveInsight.

      LAS VEGAS, March 16, 2026 /PRNewswire/ -- Recently published Neuromyelitis Optica Spectrum Disorder Market Insights report includes a comprehensive understanding of current treatment practices, neuromyelitis optica spectrum disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

      Neuromyelitis Optica Spectrum Disorder Market Summary

      • The total neuromyelitis optica spectrum disorder treatment market size is expected to grow positively by 2036 in the leading markets.
      • The United States accounted for the largest NMOSD treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
      • The prevalence among females was 9.48 per 100,000, while among males it was 3.52 per 100,000. The study observed a female-to-male ratio of approximately 3.5:1 for NMOSD.
      • Leading NMOSD companies, such as Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, and others, are developing new NMOSD treatment drugs that can be available in the NMOSD market in the coming years. 
      • The promising NMOSD therapies in clinical trials include BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), and others.

      Discover what is the current and projected global NMOSD market size @ https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

      Key Factors Driving the Growth of the Neuromyelitis Optica Spectrum Disorder Market 

      • Improved Diagnostic Capabilities: Advances in diagnostic tools, especially biomarker testing like AQP4-IgG and MOG-IgG assays, have significantly increased diagnostic accuracy and reduced delays in identifying NMOSD cases.
      • Expansion of Targeted Therapeutic Options: The launch and approval of novel biologic therapies, such as monoclonal antibodies and complement inhibitors, that specifically target immune pathways in NMOSD have transformed treatment approaches, driving higher adoption and market demand.
      • Launch of Emerging NMOSD Drugs: The dynamics of the NMOSD market are expected to change in the coming years due to the launch of emerging therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others.

      Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the current treatment strategies for NMOSD encompass a multidisciplinary approach aimed at managing symptoms and enhancing quality of life. While there is no cure for NMOSD, interventions such as immunosuppressive therapy play a crucial role in the management of NMOSD. Recently approved therapies offer hope for future advancements in NMOSD treatment.

      Neuromyelitis Optica Spectrum Disorder Market Analysis

      • Current management strategies for NMOSD provide effective symptom control but do not offer a cure. Acute relapses are typically addressed using high-dose intravenous corticosteroids, such as methylprednisolone. 
      • Common long-term therapies include corticosteroids, azathioprine, mycophenolate mofetil, and rituximab, with azathioprine or mycophenolate mofetil often paired with low-dose steroids. For patients who do not respond adequately to intravenous corticosteroids during severe relapses, plasma exchange can be an effective alternative.
      • In July 2025, NHS England introduced a national commissioning policy that recommends and funds the use of ACTEMRA (tocilizumab) for NMOSD patients who are unable to tolerate or have not responded to earlier treatments. 
      • ACTEMRA is delivered through specialised neurology centres under NHS England. Although tocilizumab had previously been authorized by the MHRA for several inflammatory conditions, it had not been specifically approved for NMOSD in the UK until this policy.
      • In the United States, FDA-approved treatments for NMOSD include ENSPRYNG, ULTOMIRIS, and others. 
      • Additionally, emerging pipeline therapies, such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others, are contributing to ongoing innovation in the NMOSD treatment landscape.

      Neuromyelitis Optica Spectrum Disorder Competitive Landscape

      Some of the NMOSD drugs under development include BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others.

      Bio-Thera Solutions' BAT4406F is an investigational, Phase II glyco-engineered monoclonal antibody being studied in China. The treatment is designed to boost antibody-dependent cellular cytotoxicity (ADCC). As a type I anti-CD20 antibody, it promotes B-cell depletion through complement-dependent cytotoxicity while enhancing ADCC, and is currently under evaluation for autoimmune conditions such as NMOSD.

      RemeGen/Vor Bio's Telitacicept (RC18) is an innovative fusion protein developed for the treatment of autoimmune disorders. It is composed of the extracellular domain of the human TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) receptor fused to the Fc portion of human IgG. Telitacicept is engineered to block two signaling molecules essential to B-cell maturation, BLyS and APRIL.

      Biocad's BCD-132 (divozilimab) is a monoclonal antibody and a novel investigational therapy being developed for multiple sclerosis and other autoimmune conditions. Monoclonal antibodies are laboratory-engineered proteins modeled on the natural antibodies produced by the immune system, each designed to bind specifically to a particular target in the body.

      For BCD-132, the target is the CD20 protein found on B cells. When BCD-132 attaches to CD20, it triggers the elimination of these B cells, lowering their numbers and thereby reducing immune activity associated with autoimmune diseases. Divozilimab's safety and effectiveness have been evaluated in preclinical animal studies, and clinical trials in humans are currently ongoing.

      The anticipated launch of these emerging therapies are poised to transform the NMOSD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the NMOSD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about are new drugs upcoming in NMOSD pipeline @ Neuromyelitis Optica Spectrum Disorder Drugs 

      What is Neuromyelitis Optica Spectrum Disorder?

      Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition in which the body's immune system mistakenly attacks the central nervous system, primarily targeting the optic nerves and spinal cord. This leads to episodes of optic neuritis, causing vision loss or eye pain, and transverse myelitis, which can result in limb weakness, sensory changes, or problems with bladder and bowel control. NMOSD is often associated with antibodies against a protein called aquaporin-4 (AQP4), which helps distinguish it from similar conditions like multiple sclerosis. Because attacks can be severe and cause lasting disability, early diagnosis and long-term treatment to prevent relapses are essential for managing the disorder effectively.

      Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

      The NMOSD epidemiology section provides insights into the historical and current NMOSD patient pool and forecasted trends for the leading markets. The diagnosed prevalence rate of NMOSD is estimated at nearly 1.5 per 100,000 population. Between 70–80% of NMOSD patients will have anti-AQP4 antibodies.

      The NMOSD treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

      • Total Prevalent Cases of NMOSD
      • Total Diagnosed Prevalent Cases of NMOSD
      • Gender-specific Diagnosed Prevalent Cases of NMOSD
      • Treated Cases of NMOSD

      Neuromyelitis Optica Spectrum Disorder Market Report Metrics

      Details

      Study Period

      2022–2036

      Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

      Total Prevalent Cases of NMOSD, Total Diagnosed Prevalent Cases of NMOSD, Gender-specific Diagnosed Prevalent Cases of NMOSD, and Treated Cases of NMOSD 

      Key Neuromyelitis Optica Spectrum Disorder Companies

      Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, Genentech, Chugai Pharmaceuticals, AstraZeneca, Alexion, and others

      Key Neuromyelitis Optica Spectrum Disorder Therapies

      BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), ENSPRYNG, ULTOMIRIS, SOLIRIS, and others

      Scope of the Neuromyelitis Optica Spectrum Disorder Market Report

      • Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and emerging therapies
      • Neuromyelitis Optica Spectrum Disorder Market Dynamics: Key Market Forecast Assumptions of Emerging Neuromyelitis Optica Spectrum Disorder Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Neuromyelitis Optica Spectrum Disorder Market Access and Reimbursement

      Download the report to understand what market trends are shaping NMOSD over the next decade @ Neuromyelitis Optica Spectrum Disorder Market Analysis

      Table of Contents

      1

      Neuromyelitis Optica Spectrum Disorder Market Key Insights

      2

      Neuromyelitis Optica Spectrum Disorder Market Report Introduction

      3

      NMOSD Market Overview at a Glance

      3.1

      Market Share (%) Distribution of NMOSD by Therapies in the 7MM in 2025

      3.2

      Market Share (%) Distribution of NMOSD by Therapies in the 7MM in 2036

      4

      Methodology

      5

      Executive Summary

      6

      Key Events

      7

      Disease Background and Overview: NMOSD

      7.1

      Introduction

      7.2

      Classification

      7.3

      Causes

      7.4

      Signs and Symptoms

      7.5

      Pathophysiology

      7.6

      Clinical features

      7.7

      Diagnosis

      7.8

      Treatment and Management

      8

      Epidemiology and Patient Population of NMOSD in the 7MM

      8.1

      Key Findings

      8.2

      Assumptions and Rationale

      8.3

      Total Prevalent Cases of NMOSD in the 7MM

      8.4

      Total Diagnosed Prevalent Cases of NMOSD in the 7MM

      8.5

       The US

      8.5.1

       Total Prevalent Cases of NMOSD

      8.5.2

       Total Diagnosed Prevalent Cases of NMOSD

      8.5.3

       Gender-specific Diagnosed Prevalent Cases of NMOSD

      8.5.4

       Treated Cases of NMOSD

      8.6

       EU4 and the UK

      8.7

      Japan

      9

      NMOSD Patient Journey

      10

      Marketed NMOSD Therapies

      10.1

      Key Cross Competition

      10.2

      ENSPRYNG: Genentech/Chugai Pharmaceuticals

      10.2.1

      Product Description

      10.2.2

      Product Profile

      10.2.3

      Other Developmental Activities

      10.2.4

      Clinical Trials Information

      10.2.5

      Safety and Efficacy

      10.3

      ULTOMIRIS: AstraZeneca

      10.4

      SOLIRIS: Alexion/AstraZeneca

      List to be continued in the final report.

      11

      Emerging NMOSD Therapies

      11.1

      Key Cross Competition

      11.2

      BAT4406F: Bio-Thera Solutions

      11.2.1

      Drug Description

      11.2.2

      Product Profile

      11.2.3

      Other Developmental Activities

      11.2.4

      Clinical Trials Information

      11.2.5

      Safety and Efficacy

      11.3

      Telitacicept (RC18): RemeGen/Vor Bio

      List to be continued in the final report.

      12

      NMOSD: Market Analysis

      12.1

      Key Findings

      12.2

      Key Neuromyelitis Optica Spectrum Disorder Market Forecast Assumptions

      12.3

      Neuromyelitis Optica Spectrum Disorder Market Outlook

      12.4

      Conjoint Analysis

      12.5

      Total Market Size of NMOSD in the 7MM

      12.6

      Market Size of NMOSD by Therapies in the 7MM

      12.7

      The US Neuromyelitis Optica Spectrum Disorder Market

      12.8.1

      Total Market Size of NMOSD

      12.8.2

      Market size of NMOSD by Therapies

      12.8

      EU4 and the UK Neuromyelitis Optica Spectrum Disorder Market 

      12.9

      Japan Neuromyelitis Optica Spectrum Disorder Market 

      12.9.1

      Total Market Size of NMOSD

      12.9.2

      Market size of NMOSD by Therapies

      13

      Key Opinion Leaders' Views on NMOSD

      14

      NMOSD Market SWOT Analysis

      15

      NMOSD Market Unmet needs

      16

      Market Access and Reimbursement

      16.1

      The US

      16.2

      In EU4 and the UK

      16.3

      Japan

      17

      Acronyms and Abbreviations

      18

      Bibliography

      19

      Neuromyelitis Optica Spectrum Disorder Market Report Methodology

      Related Reports

      Neuromyelitis Optica Spectrum Disorder Clinical Trial Analysis

      Neuromyelitis Optica Spectrum Disorder Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NMOSD companies, including Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Xiniao Biotech Co., Ltd., and others.

      Multiple Sclerosis Market

      Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, and others.

      Relapsing-Remitting Multiple Sclerosis Market

      Relapsing-Remitting Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, and others.

      CD40/CD40L Inhibitors Market

      CD40/CD40L Inhibitors Market, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CD40/CD40L inhibitors companies including Sanofi, UCB, Amgen, Eledon Pharmaceuticals, Kiniksa Pharmaceuticals, Memgen, and others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us
      Shruti Thakur
      [email protected]
      +14699457679
      www.delveinsight.com

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.